Trump's International Pricing Proposal Being Revised To Adopt ‘Most Favored Nation’ Policy – Azar
Executive Summary
HHS Secretary Alex Azar says that reshaping Administration’s upcoming proposed rule would drive Medicare Part B drug prices even lower than previously projected. As Part B drug costs are being blamed for higher premiums, the policy revisions are at OMB, but plan would reemerge as "a notice of proposed rulemaking if that comes out,” Azar said.
You may also be interested in...
US Senate Finance Drug Pricing Bill Would Have ‘Negligible’ Impact, Analyst Predicts
Now that US drug pricing reform seems inevitable, the Senate bill offers the most positive outcome for industry, Bernstein analyst Ronny Gal suggests.
US Drug Importation: Hard To See Path Forward, Former HHS Adviser Says
Former drug pricing advisor John O’Brien discusses next steps for Administration policies around importation and international reference pricing during a speech to the Academy of Managed Care Pharmacy.
White House Exec Order Will Bring US Parity With Lowest Drug Prices Abroad, Trump Says
Remarks to reporters prompt surprise and confusion among stakeholders and likely reflect the president’s impatience with the pace of regulatory and legislative pricing reforms.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests:
